Skip to Content
 
Javid. J.   Moslehi

Javid. J. Moslehi, M.D.

Assistant Professor of Medicine
Director, Cardio-Oncology Program
Cardio-Oncologist

Profile

Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.
Read more...

Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital. Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.

Education
  • M.D., University of Connecticut School of Medicine (2001)
  • Residency, Internal Medicine: Johns Hopkins Hospital (Janeway Firm)
  • Fellowship, Cardiology: Brigham and Women's Hospital/Harvard Medical School
 
Publications
  • Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation. 2016 Mar 3/1/2016; 133(9): 908-12. PMID: 26927008, PII: CIRCULATIONAHA.115.018351, DOI: 10.1161/CIRCULATIONAHA.115.018351, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26927008.
  • Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation. 2016 Mar 3/1/2016; 133(9): 908-12. PMID: 26927008, PII: CIRCULATIONAHA.115.018351, DOI: 10.1161/CIRCULATIONAHA.115.018351, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26927008.
  • Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG. EGLN1 Inhibition and Rerouting of a-Ketoglutarate Suffice for Remote Ischemic Protection. Cell. 2016 Feb 2/25/2016; 164(5): 884-95. PMID: 26919427, PII: S0092-8674(16)30072-1, DOI: 10.1016/j.cell.2016.02.006, ISSN: 1097-4172.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26919427.
  • Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG. EGLN1 Inhibition and Rerouting of a-Ketoglutarate Suffice for Remote Ischemic Protection. Cell. 2016 Feb 2/25/2016; 164(5): 884-95. PMID: 26919427, PII: S0092-8674(16)30072-1, DOI: 10.1016/j.cell.2016.02.006, ISSN: 1097-4172.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26919427.
  • Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016 Feb 2/2/2016; 133(5): 537-41. PMID: 26831435, PII: CIRCULATIONAHA.115.012519, DOI: 10.1161/CIRCULATIONAHA.115.012519, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26831435.
  • Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016 Feb 2/2/2016; 133(5): 537-41. PMID: 26831435, PII: CIRCULATIONAHA.115.012519, DOI: 10.1161/CIRCULATIONAHA.115.012519, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26831435.
  • Scott JM, Armenian S, Giralt S, Moslehi J, Wang T, Jones LW. Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Crit. Rev. Oncol. Hematol [print-electronic]. 2016 Feb; 98: 222-34. PMID: 26643524, PII: S1040-8428(15)30077-9, DOI: 10.1016/j.critrevonc.2015.11.007, ISSN: 1879-0461.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26643524.
  • Scott JM, Armenian S, Giralt S, Moslehi J, Wang T, Jones LW. Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Crit. Rev. Oncol. Hematol [print-electronic]. 2016 Feb; 98: 222-34. PMID: 26643524, PII: S1040-8428(15)30077-9, DOI: 10.1016/j.critrevonc.2015.11.007, ISSN: 1879-0461.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26643524.
  • Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan 1/1/2016; 2(1): 29-36. PMID: 26539793, PII: 2467066, DOI: 10.1001/jamaoncol.2015.3709, ISSN: 2374-2445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26539793.
  • Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan 1/1/2016; 2(1): 29-36. PMID: 26539793, PII: 2467066, DOI: 10.1001/jamaoncol.2015.3709, ISSN: 2374-2445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26539793.
  • Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J. Clin. Oncol [print-electronic]. 2015 Dec 12/10/2015; 33(35): 4210-8. PMID: 26371140, PMCID: PMC4658454, PII: JCO.2015.62.4718, DOI: 10.1200/JCO.2015.62.4718, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26371140.
  • Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 2015 Dec 12/8/2015; 132(23): 2248-58. PMID: 26644247, PII: CIRCULATIONAHA.115.010484, DOI: 10.1161/CIRCULATIONAHA.115.010484, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26644247.
  • Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J. Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. Circulation. 2015 Nov 11/3/2015; 132(18): e218-20. PMID: 26527696, PII: CIRCULATIONAHA.115.012521, DOI: 10.1161/CIRCULATIONAHA.115.012521, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26527696.
  • Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J. Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. Circulation. 2015 Nov 11/3/2015; 132(18): e218-20. PMID: 26527696, PII: CIRCULATIONAHA.115.012521, DOI: 10.1161/CIRCULATIONAHA.115.012521, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26527696.
  • Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J. Am. Coll. Cardiol. 2015 Sep 9/8/2015; 66(10): 1160-78. PMID: 26337996, PII: S0735-1097(15)04515-5, DOI: 10.1016/j.jacc.2015.07.025, ISSN: 1558-3597.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26337996.
  • Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J. Am. Coll. Cardiol. 2015 Sep 9/8/2015; 66(10): 1160-78. PMID: 26337996, PII: S0735-1097(15)04515-5, DOI: 10.1016/j.jacc.2015.07.025, ISSN: 1558-3597.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26337996.
  • Fradley MG, Moslehi J. QT Prolongation and Oncology Drug Development. Card Electrophysiol Clin [print-electronic]. 2015 Jun; 7(2): 341-55. PMID: 26002398, PII: S1877-9182(15)00042-8, DOI: 10.1016/j.ccep.2015.03.013, ISSN: 1877-9190.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26002398.
  • Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J. Am. Coll. Cardiol. 2015 Feb 2/17/2015; 65(6): 573-83. PMID: 25677317, PII: S0735-1097(14)07283-0, DOI: 10.1016/j.jacc.2014.11.035, ISSN: 1558-3597.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25677317.
  • Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J. ABCDE steps to prevent heart disease in breast cancer survivors. Circulation. 2014 Oct 10/28/2014; 130(18): e157-9. PMID: 25462826, PII: 130/18/e157, DOI: 10.1161/CIRCULATIONAHA.114.008820, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25462826.
  • Koelwyn GJ, Jones LW, Moslehi J. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary [editorial]. J. Am. Coll. Cardiol. 2014 Sep 9/30/2014; 64(13): 1320-2. PMID: 25257632, PII: S0735-1097(14)05623-X, DOI: 10.1016/j.jacc.2014.07.949, ISSN: 1558-3597.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25257632.
  • Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG, Zhang Q. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev. 2014 Jul 7/1/2014; 28(13): 1429-44. PMID: 24990963, PMCID: PMC4083087, PII: 28/13/1429, DOI: 10.1101/gad.242131.114, ISSN: 1549-5477.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24990963.
  • Unitt C, Montazeri K, Tolaney S, Moslehi J. Cardiology patient page. Breast cancer chemotherapy and your heart. Circulation. 2014 Jun 6/24/2014; 129(25): e680-2. PMID: 24958758, PII: 129/25/e680, DOI: 10.1161/CIRCULATIONAHA.113.007181, ISSN: 1524-4539.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24958758.
  • Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014 Mar 3/1/2014; 28(5): 479-90. PMID: 24589777, PMCID: PMC3950345, PII: 28/5/479, DOI: 10.1101/gad.231233.113, ISSN: 1549-5477.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24589777.
  • Francis SA, Cheng S, Arteaga CL, Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment [editorial]. J Am Heart Assoc. 2014 Feb; 3(1): e000780. PMID: 24584746, PMCID: PMC3959702, PII: jah3455, DOI: 10.1161/JAHA.113.000780, ISSN: 2047-9980.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24584746.
  • Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013 Dec 12/19/2013; 155(7): 1624-38. PMID: 24360282, PMCID: PMC4076149, PII: S0092-8674(13)01521-3, DOI: 10.1016/j.cell.2013.11.037, ISSN: 1097-4172.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24360282.